http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107445938-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2016-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107445938-B |
| titleOfInvention | Crystalline form of eliglutacoside hemitartrate, process for its preparation and pharmaceutical compositions containing it |
| abstract | The invention provides a crystalline form of eletriptan hemitartrate shown as a formula I (a), a preparation method thereof and a pharmaceutical composition containing the crystalline form, wherein X-ray powder diffraction of the crystalline form of the eletriptan hemitartrate has main characteristic peaks at the positions with 2 theta angles of 10.2 degrees, 12.4 degrees, 13.6 degrees, 14.9 degrees, 20.1 degrees and 22.1 degrees, a DSC (differential scanning calorimetry) spectrum shows that an endothermic peak exists at 161-162 ℃, the crystalline form of the eletriptan hemitartrate has the advantage of good stability, the prepared pharmaceutical composition has the advantage of good dissolution, and the crystal is suitable for being used as a raw material medicament for production and storage of pharmaceutical preparations. I(a)。 |
| priorityDate | 2016-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.